MarketPulse

uveal melanoma

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Immunocore Holdings Plc

Immunocore's KIMMTRAK Doubles Five-Year Survival Rate, Posts 14% Revenue Growth

Immunocore reports $106.7M Q1 KIMMTRAK sales, up 14% YoY, with landmark data showing doubled five-year survival in uveal melanoma patients.
IMCRPhase 3 trialimmunotherapy
BenzingaBenzinga··Vandana Singh

IDEAYA's Eye Cancer Drug Combo Demolishes Standard Therapy in Pivotal Trial

$IDYA's darovasertib-crizotinib combination doubled progression-free survival in metastatic uveal melanoma versus standard care, with FDA submission planned for late 2026.
IDYAFDA approvalprogression-free survival
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Immunocore Lines Up Five Major Investor Conferences in March 2026

Immunocore Holdings announced presentations at five major investor conferences in March 2026, showcasing its commercial-stage biotech platform and pipeline to institutional investors.
IMCRinvestor conferencesfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Immunocore to Present FY2025 Results and Business Update on Feb. 25

Immunocore will report FY2025 results and business updates on February 25, 2026, via teleconference. The biotech firm will discuss commercial progress for its approved KIMMTRAK treatment and pipeline advancement.
IMCRfinancial resultsQ4 2025